Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with ...

Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more ...

This discussion features BioSpace’s head of insights Lori Ellis, Kearney partner Martin Hadosi, and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine examining the ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the ...

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...